# A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

> **NCT05276063** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Sling Therapeutics, Inc.** · enrollment: 90 (actual)

## Conditions studied

- Thyroid Eye Disease
- Graves Orbitopathy
- Endocrine System Diseases
- Eye Diseases
- Thyroid Associated Ophthalmopathy
- Graves Ophthalmopathy
- Thyroid Diseases
- Orbital Diseases
- Proptosis
- IGF1R
- Exophthalmos
- Hashimoto

## Interventions

- **DRUG:** Linsitinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05276063
- **Lead sponsor:** Sling Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-07-01
- **Primary completion:** 2024-10-15
- **Final completion:** 2026-09
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2025-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05276063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05276063, "A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT05276063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*